ZymoGenetics Builds New R&D Facility | GenomeWeb

SEATTLE--ZymoGenetics Inc. has begun construction of a new 46,000-square-foot, $12 million R&D facility located adjacent to the company's headquarters. The new building will later be expanded to 78,500 square feet.

ZymoGenetics is the North American Health Care Drug Discovery unit of the Danish pharmaceutical company Novo Nordisk A/S. It employs over 250 staff in the pursuit of bioinformatics-driven discovery of therapeutic proteins.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.